论文部分内容阅读
目的观察精蛋白生物合成人胰岛素联合格列美脲治疗对单纯口服降糖药疗效差的2型糖尿病患者的临床疗效和安全性。方法将64例对单纯口服降糖药疗效差的2型糖尿病患者随机分为2组,每组32例。治疗组给予精蛋白生物合成人胰岛素和格列美脲,对照组给予双时相低精蛋白锌胰岛素,疗程均为12周。观察2组治疗前后空腹血糖(FPG)、餐后2 h血糖(2hPPG)、糖化血红蛋白C(Hb_(AlC))的变化。结果治疗前2组FPG、2hPPG、Hb_(Alc)比较差异均无统计学意义(P>0.05)。治疗后,2组FPG、2hPPG、Hb_(AlC)与治疗前比较差异均有统计学意义(P<0.05);而组间比较,2组PPG、Hb_(AlC)之间差异具有统计学意义(P<0.05)。治疗组发生低血糖的比例(1/32)低于对照组(4/32),差异有统计学意义(P<0.05)。结论精蛋白生物合成人胰岛素联合格列美脲治疗对单纯口服降糖药疗效差的2型糖尿病患者,疗效优于使用双时相低精蛋白锌胰岛素者,且低血糖发生率低。
Objective To observe the clinical efficacy and safety of protamine biosynthesis human insulin combined with glimepiride in the treatment of type 2 diabetic patients with poor oral glucose tolerance. Methods Sixty-four patients with type 2 diabetes mellitus who were treated with oral hypoglycemic agents were randomly divided into two groups (n = 32 in each group). The treatment group was given protamine biosynthesis of human insulin and glimepiride, the control group was given dual-phase hypophosphatemia insulin, treatment for 12 weeks. The changes of fasting blood glucose (FPG), 2h postprandial blood glucose (2hPPG), and glycosylated hemoglobin C (Hb_ (AlC)) in two groups before and after treatment were observed. Results There was no significant difference in FPG, 2h PPG and Hb_ (Alc) between the two groups before treatment (P> 0.05). After treatment, the differences of FPG, 2hPPG and Hb_ (AlC) between the two groups were statistically significant (P <0.05), while there were significant differences between the two groups in PPG and Hb_ (AlC) (P < P <0.05). The incidence of hypoglycemia in the treatment group (1/32) was lower than that in the control group (4/32), the difference was statistically significant (P <0.05). Conclusion The combination of protamine biosynthesis human insulin and glimepiride is superior to those of patients with type 2 diabetes mellitus with poor oral hypoglycemic agents, and the incidence of hypoglycemia is low.